<DOC>
	<DOCNO>NCT02599714</DOCNO>
	<brief_summary>This dose finding/extension study consist three part : Part A identify MTD AZD2014/palbociclib combination background fulvestrant ( referred triplet ) postmenopausal woman locally advanced/metastatic estrogen receptor positive ( ER+ ) breast cancer . Part B characterize safety , tolerability , PK , preliminary efficacy single-arm dose expansion group . Part C investigate efficacy triplet combination double-blind , placebo-controlled , stratified , parallel group extension .</brief_summary>
	<brief_title>Study AZD2014 Palbociclib Patients With Estrogen Receptor Positive ( ER+ ) Metastatic Breast Cancer</brief_title>
	<detailed_description>This Phase I/II international , multicenter study combination AZD2014 palbociclib background 500 mg fulvestrant ( referred triplet ) postmenopausal woman locally advanced/metastatic estrogen receptor positive ( ER+ ) breast cancer . The study consist three part : Part A Phase I triplet-dose find investigation 3-6 patient per cohort determine maximum tolerate dose ( MTD ) triplet . Part B comprise Phase I single arm expansion approx 27 patient evaluable response define recommend Phase II dose ( RP2D ) . Part C investigate efficacy triplet combination RP2D randomize , double-blind , placebo-controlled , stratified , parallel group extension . Part C include ER+ , locally advanced and/or metastatic breast cancer patient progress follow prior non-steroidal aromatase inhibitor ( NSAI ) endocrine therapy . Patients Part C randomize receive either triplet combination ( AZD2014 + palbociclib + fulvestrant ) doublet ( match AZD2014 placebo + palbociclib + fulvestrant ) . Patients stratify accord hormone sensitivity , presence visceral metastasis , prior CDK inhibitor treatment . Part C open indicated emerge data</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Inclusion : Postmenopausal woman &gt; = 18 WHO/ECOG perf . status 01 Histologically cytologically proven diagnosis breast cancer evidence locally advance metastatic disease amendable resection radiation ER+ HER2 negative Parts A : Must eligible fulvestrant . A maximum 3 prior line chemotherapy allow Parts B C : Postmenopausal locally advance metastatic ER+ breast cancer refractory aromatase inhibitor ( AIs ) , define : disease recurrence , within 12 month end adjuvant treatment letrozole , anastrazole , exemestane ; disease progression , within one month end letrozole , anastrazole , exemestane , exemestane treatment locally advance metastatic breast cancer . At least 1 lesion ( measurable non measurable ) accurately assessed baseline CT MRI suitable accurate repeat measurement Exclusion : Prior chemotherapy , biological radiation therapy , androgen , thalidomide , immunotherapy , anticancer agent , investigational drug corticosteroid within 14 day Prior radiotherapy &gt; = 25 % bone marrow regardless receive Unresolved toxicity prior therapy &gt; CTCAE grade 1 Exposure potent moderate inhibitor inducer CYP3A4/5 , CYP2C8 , Pgp ( MDR1 ) BCRP take within state washout period prior start treatment Exposure sensitive narrow therapeutic range substrate drug transporter OATP1B1 , OATP1B3 , MATE1 MATE2K within appropriate washout period ( minimum 5 x report elimination halflife ) first dose study treatment Previous treatment AZD2014 , AZD8055 mTORC1/2 inhibitor , Part C : Prior treatment fulvestrant , everolimus , agent whose mechanism action inhibit PI3KmTOR pathway Prior treatment CDK4/6 , everolimus PI3KmTOR pathway Major surgery significant trauma within 4 week anticipate need major surgery study , minor surgery within 2 week study entry Known active uncontrolled symptomatic CNS metastasis , carcinomatous meningitis , leptomeningeal disease , indicate clinical symptom , cerebral edema , and/or progressive growth . History CNS metastases cord compression eligible definitively treat ( e.g . radiotherapy , stereotactic surgery ) clinically stable , anticonvulsant steroids least 4 week . Not eligible spinal cord compression and/or brain metastasis unless asymptomatic treat stable steroid least 4 week . Any evidence severe uncontrolled systemic disease judge Investigator . Any malignancy within 3 year prior study treatment , except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix . Any follow currently within 12 month : coronary/peripheral artery bypass graft , angioplasty , vascular stent , MI , angina , CHF ( NYHA Grade &gt; =2 ) , ventricular arrhythmia require continuous therapy , supraventricular arrhythmia include atrial fibrillation , symptomatic pulmonary embolism , haemorrhagic thrombotic stroke , include TIA CNS bleed Abnormal ECHO MUGA baseline ( LVEF &lt; 50 % ) Mean rest QTc &gt; 470 msec , family personal history long short QT syndrome , Brugada syndrome know history QTc prolongation Torsade de Pointes within 12 month Any clinically important abnormality rhythm , conduction , morphology rest ECG , e.g . complete leave bundle branch block , third degree heart block . Concomitant medication know prolong QT , factor increase risk QTc prolongation risk arrhythmic event heart failure , hypokalemia , congenital long QT syndrome , family history long QT syndrome , family history unexplained sudden death age 40 . Inadequate bone marrow reserve organ function demonstrate follow : ANC &lt; 1.5 x 109/L , platelet &lt; 100x109/L , haemoglobin &lt; 90g/L , ALT &gt; 2.5 x ULN &gt; 5 x ULN presence liver metastasis , total bilirubin &gt; 1.5 x ULN &gt; 3 x ULN patient Gilbert 's Syndrome , serum creatinine &gt; 1.5 x ULN concurrent creatinine clearance &lt; = 50 mL/min . Part A Only : Individual cohort may specific baseline ANC range patient enrol within limit exclusion . These subgroup define follow Low ANC Patients : ANC 1.5 x 10^9/L 3.0 x 10^9/L High ANC Patients : ANC 3.0 x 10^9/L Preexisting renal disease include glomerulonephritis , nephritic syndrome , Fanconi Syndrome renal tubular acidosis . Refractory nausea vomiting , chronic GI disease , inability swallow product , previous significant bowel resection would preclude adequate absorption AZD2014 palbociclib . History hypersensitivity active inactive excipients AZD2014 , palbociclib fulvestrant , drug similar chemical structure Patients Diabetes Type I uncontrolled Type II Patients advanced/metastatic , symptomatic , visceral spread , risk lifethreatening complication short term include patient massive uncontrolled effusion ( pleural , pericardial , peritoneal ) , pulmonary lymphangitis , 50 % liver involvement metastasis . Prior hematopoietic stem cell bone marrow transplant Patients receive regular coumadin therapy ( LMW heparin allow ) Known coagulation abnormality Erythropoietin , GCSF , GMCSF allow within 2 week prior study . The primary prophylactic use GCSF permit may use treat treatmentemergent neutropenia .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AZD2014 , Palbociclib , Fulvestrant , Hormonal Therapy , Estrogen , Receptor , Positive , Locally-Advanced , Metastatic , Breast Cancer</keyword>
</DOC>